




AUDITED FINANCIAL RESULTS FOR EIGHTEEN MONTHS ENDED MARCH 31, 2015

Sl. No.		Particulars	Three months ended			18 months ended 31-Mar-2015 (Audited)	18 months ended 30-Sep-2013 (Audited)	Consolidated for 18 months ended 31-Mar-2015 (Audited)	Consolidated for 18 months ended 30-Sep-2013 (Audited)
			31-Mar-2015 (Unaudited)	31-Dec-2014 (Unaudited)	31-Mar-2014 (Unaudited)				
1		Net Sales / Income from Operations (Net of Excise Duty)	28,293.87	15,902.21	44,845.65	1,84,950.03	1,71,441.78	1,89,256.33	
2		Other Operating Income	2,183.95	551.31	426.92	9,684.05	4,972.28	9,584.10	
3		Total Operating Income (1+2)	30,477.82	16,453.52	45,272.57	1,94,634.08	1,76,414.06	1,98,840.43	
4		Expenditure	19,351.27	12,592.96	17,266.42	82,246.39	81,995.79	85,468.99	
		a) Cost of materials consumed	4.69	11.65	44.20	5,059.37	277.39	5,062.03	
		b) Purchases of stock-in-trade	(3,697.74)	(5,642.23)	5,027.02	8,481.03	(4,370.37)	8,481.03	
		c) Changes in Inventories of finished goods, work-in-progress and stock-in-trade	2,137.61	2,134.75	2,714.58	18,534.86	19,338.04	25,270.13	
		d) Employees Cost	6,027.21	4,430.18	5,717.44	24,386.87	32,458.46	25,192.28	
		e) Depreciation / Amortisation	3,986.17	4,645.65	9,378.86	42,565.12	43,290.23	59,461.39	
		f) Other Expenditure	27,809.21	18,172.96	40,148.52	1,71,370.29	1,72,989.54	2,08,935.85	
		g) Total	2,668.61	(1,719.44)	5,124.05	(7,426.54)	3,424.52	(10,095.42)	
5		Profit / (Loss) from Operations before Other Income, Interest, Exceptional Item (3-4)	6.20	1.01	1.16	1.31	93.28	1.59	
6		Other Income	2,674.81	(1,718.43)	5,125.21	(7,425.23)	3,517.80	(10,093.83)	
7		Profit / (Loss) before Interest & Exceptional Item (5+6)	10,452.60	7,456.44	10,202.27	53,700.87	53,712.45	52,268.71	
8		Finance cost	(7,777.79)	(9,174.87)	(5,077.06)	(49,461.66)	(50,194.65)	(62,362.54)	
9		Profit/(loss) after interest but before Exceptional Item (7-8)	(10,093.46)	(5,230.19)	(893.75)	(15,726.30)	(15,726.30)	(5,111.08)	
10		Exceptional Item - Gain/(Loss)	(17,871.25)	(14,405.06)	(5,970.81)	(54,352.21)	(65,920.95)	(57,251.46)	
11		Profit/(Loss) before Tax (9+10) from Ordinary activities	(7,885.28)	(2,395.63)	2,108.34	(1,929.56)	(19,145.75)	(1,252.26)	
12		Tax expenses	(9,985.97)	(12,009.43)	(8,079.15)	(53,022.65)	(46,775.20)	(55,999.20)	
13		- Current Tax & Deferred Tax	(4,818.99)	-	-	-	27,061.78	-	
14		Profit/(Loss) after Tax (11-12) from Ordinary activities	(14,804.96)	(12,009.43)	(8,079.15)	(53,022.65)	(19,713.42)	(55,999.20)	
15		Extra-ordinary Items - Gain/(Loss) (Net of Tax)	-	-	-	-	(13.63)	(196.50)	
16		Net Profit/(Loss) for the period (13+14)	(14,804.96)	(12,009.43)	(8,079.15)	(53,022.65)	(19,727.05)	(56,165.70)	
17		Share of Profit / (Loss) in Associate	-	-	-	-	(61.82)	-	
18		Less: Minority Interest	(14,804.96)	(12,009.43)	(8,079.15)	(53,022.65)	(19,665.22)	(55,802.70)	
19		Net Profit/(Loss)	8,526.19	8,526.19	7,045.21	7,045.21	8,526.19	7,045.21	
20		Paid-up Equity Share Capital	-	-	-	41,771.33	24,412.07	30,953.46	
21		Reserves excluding Revaluation Reserves	(11.71)	(14.09)	(11.47)	(75.26)	(63.94)	(79.21)	
22		Earnings per share (EPS) before extra-ordinary item	(11.71)	(14.09)	(11.47)	(75.26)	(63.94)	(79.21)	
		- Basic Rs.*	(17.36)	(14.09)	(11.47)	(75.26)	(63.94)	(79.21)	
		- Diluted Rs.*	(17.36)	(14.09)	(11.47)	(75.26)	(63.94)	(79.21)	

* EPS for the period (not annualised)




AUDITED FINANCIAL RESULTS FOR EIGHTEEN MONTHS ENDED MARCH 31, 2015

Sl.No	Particulars	As at 31-Mar-2015	As at 31-Dec-2014	As at 31-Mar-2014	As at 31-Mar-2015	As at 30-Sep-2013	As at 31-Mar-2015	As at 30-Sep-2013
* EPS for the period (not annualised)								
A	PARTICULARS OF SHAREHOLDING							
1	Public Shareholding	47,711,285	47,711,285	47,711,285	47,711,285	47,711,285	47,711,285	47,711,285
	- Number of equity shares	55.98	87.72	87.72	55.98	67.72	55.98	67.72
2	Promoters and Promoter group shareholding	34,828,453	35,433,453	17,531,400	34,828,453	18,941,608	34,828,453	18,941,608
	a. Pledged / Encumbered							
	- Number of shares							
	- Percentage of shares (as a % of the total shareholding of Promoter and Promoter group)	92.21	94.36	77.09	92.21	83.29	92.21	83.29
	- Percentage of shares (as a % of the total share capital of the company)	40.61	41.56	24.88	40.61	26.89	40.61	26.89
	b. Non - Encumbered							
	- Number of shares	2,922,129	2,117,129	5,208,381	2,922,128	3,789,173	2,922,129	3,789,173
	- Percentage of shares (as a % of the total shareholding of Promoter and Promoter group)	7.78	5.64	22.81	7.78	16.71	7.78	16.71
	- Percentage of shares (as a % of the total share capital of the company)	3.43	2.48	7.40	3.43	5.39	3.43	5.39

Sl.No	Particulars	As at 31-Mar-2015	As at 31-Dec-2014	As at 31-Mar-2014	As at 31-Mar-2015	As at 30-Sep-2013	As at 31-Mar-2015	As at 30-Sep-2013
PARTICULARS								
B	INVESTOR COMPLAINTS							
	- Pending at the beginning of the quarter							
	- Received during the quarter							
	- Disposed of during the quarter							
	- Remaining unresolved at the end of the quarter							

1	The above audited financial results have been reviewed by the Audit Committee and approved by the Board of Directors at the meeting held on May 28, 2015							
2	The Company is operating in single segment (i.e) "Pharmaceuticals".							
3	The Company's Corporate Debt Restructuring package, approved by the CDR Empowered Group vide its Letter of Approval Dt. 10/03/2014, has been implemented in July 2014.							
4	The wholly owned subsidiary Orchid Singapore Pte Limited, Singapore has been wound up.							
5	Exceptional items for three months ended March 31, 2015 represents amortisation of exchange loss on restatement of Foreign currency loans amounting to Rs.1093.46 Lakhs, Provision for contingencies relating to transferred business amounting to Rs.6000 Lakhs and one time management fee paid amounting to Rs.3000 Lakhs.							
6	The Company had exercised the option provided under the Companies (Accounting Standards) Amendment Rules, 2006 dated March 31, 2009. The Ministry of Corporate Affairs vide notification dated 28/12/2011 has extended the amortisation of gains or losses arising on reporting of foreign currency monetary items over the balance period of such long term asset/liability. Accordingly exchange loss on long term foreign currency loans have been amortised over the balance period of such loans. The amount remaining to be amortised in the financial statements as at March 31, 2015 on account of exercising the above option is Rs.10,604.32 Lakhs.							
7	The extraordinary item for the quarter represents additional tax impact on sale of undertaking and for eighteen months represents profit on sale of undertaking.							




[Handwritten Signature]



AUDITED FINANCIAL RESULTS FOR EIGHTEEN MONTHS ENDED MARCH 31, 2015

	Rs. lakhs
8	The increase in interest for the quarter ending 31/03/2015 is due to additional interest provisions made based on confirmation statement of accounts received from various banks during the current period.
9	The auditors have observed matters relating to recovery of certain advances paid to suppliers, non-provision of diminution in value of investments in foreign R&D subsidiaries and non provision of amount due from marketing subsidiary. The Corporate Debt Restructuring scheme already approved has been implemented in July 2014. Due to financial constraints, the Company was not able to take delivery of materials/capital goods and the company is confident that with the COR implementation, the company would be able to take delivery of these materials in due course. As far as the diminution in value of investments is concerned, the Company is confident that the value of molecules held by the foreign subsidiaries will be more than the investment. In respect of dues from the marketing subsidiary, the Company has already started exporting and selling profitable products through its marketing subsidiaries and the profit made from the operations will be available for settlement of past dues. Hence the management expects that the observations made by the auditors will not have any material impact on the financials. The Company has disputes with certain banks and hence interest on loans/facilities availed from such banks has been provided on an estimated basis.
10	The figures for the Quarter VI ended March 31, 2015 and September 30, 2013 are the balancing figure between the audited figures in respect of the full financial year (i.e. 18m ended March 31, 2015 /September 30, 2014) and the published year-to-date unaudited figures upto Quarter V (i.e. upto 18m ended December 31, 2014 /June 30, 2013) of the relevant financial year.
11	Previous period figures have been regrouped wherever necessary.

Place : Chennai
Date : May 28, 2015

For and on behalf of the Board

K. Raghavendra Rao
Managing Director





Orchid Chemicals
& Pharmaceuticals Limited

STATEMENT OF ASSETS AND LIABILITIES

Rs. Lakhs

	Particulars	Standalone Audited		Consolidated-Audited	
		As at 31-Mar-15	As at 30-Sep-13	As at 31-Mar-15	As at 30-Sep-13
A	EQUITY AND LIABILITIES				
1	Shareholders' funds				
	(a) Share Capital	8,526.19	7,045.21	8,526.19	7,045.21
	(b) Reserves and Surplus	35,413.36	41,771.33	24,412.07	30,953.46
	Sub-total- Shareholders' funds	43,939.55	48,816.54	32,938.26	37,998.67
2	Minority Interest	-	-	-	61.91
3	Non-current liabilities				
	(a) Long-term borrowings	2,49,423.99	90,178.12	2,47,806.54	90,179.41
	(b) Deferred tax liabilities (net)	11,139.30	15,788.78	11,121.45	15,737.01
	(c) Long-term provisions	417.94	523.98	417.94	523.98
	Sub-total- Non-current liabilities	2,60,981.23	1,06,490.88	2,59,345.93	1,06,440.40
4	Current liabilities				
	(a) Short-term borrowings	58,092.40	1,52,489.48	58,092.39	1,52,489.48
	(b) Trade payables	36,156.75	56,166.86	37,686.78	59,739.60
	(c) Other current liabilities	11,208.74	1,05,240.29	12,652.74	1,05,256.67
	(d) Short-term provisions	1,218.00	3,117.18	1,218.00	3,117.18
	Sub-total-Current liabilities	1,06,675.89	3,17,013.81	1,09,849.91	3,20,602.93
	TOTAL-EQUITY AND LIABILITIES	4,11,596.67	4,72,321.23	4,02,134.10	4,65,103.91
B	ASSETS				
1	Non-current assets				
	(a) Fixed assets	1,97,861.15	2,84,322.66	2,07,671.23	2,94,398.62
	(b) Non-current investments	12,464.70	12,417.62	81.19	94.82
	(c) Long-term loans and advances	58,013.50	51,101.69	58,013.50	51,158.02
	(d) Other non-current assets	12,583.67	9,310.44	12,561.22	9,310.44
	Sub-total- Non-current assets	2,80,923.02	3,57,152.41	2,78,327.14	3,54,961.90
2	Current assets				
	(a) Inventories	24,227.83	50,008.01	25,192.80	50,623.91
	(b) Trade receivables	25,011.27	18,369.69	21,651.61	17,906.39
	(c) Cash and cash equivalents	39,956.65	2,239.52	39,056.50	2,342.35
	(d) Short-term loans and advances	31,977.90	44,551.60	27,406.05	39,269.36
	(e) Other Current Assets	10,500.00	-	10,500.00	-
	Sub-total-current assets	1,30,673.65	1,15,168.82	1,23,806.96	1,10,142.01
	TOTAL ASSETS	4,11,596.67	4,72,321.23	4,02,134.10	4,65,103.91

For end on behalf of the Board

K. Raghavendra Rao
Managing Director

Place : Chennai
Date : May 28, 2015



FY15 Earnings

Chennai, India – May 28, 2015

Orchid Pharma registers turnover of Rs 1753 crore in FY15

Financial highlights for year ended March 31, 2015 (FY15) - Standalone

Revenue of Rs 1753 crore [US\$ 280.6 million] registered during the year ended March 31, 2015 (FY 13-15 /18 months) as compared to Rs 1946 crore [US\$ 311.4 million] registered during the corresponding year ended March 31, 2013 [18 months].

Earnings before Interest, Depreciation and Tax (EBIDTA) stood at Rs 361 crore [US\$ 57.8 million] for the fiscal under review compared to Rs 169.60 crore [US\$ 27.1 million] registered during FY13

Net (Loss) for the fiscal ended March 31, 2015 stood at Rs (191) crore [US\$ (30.6) million] compared to a loss of Rs (530) crore [US\$ (84.8) million] for the previous fiscal

EPS for the fiscal ended March 31, 2015 stood at Rs. (26.11)

*** 1 US\$ = Rs 62.50**

The company extended its current financial and accounting year by six months to March 31, 2015. This is to fall in line with the new Companies Act requirement.

Update on the Corporate Debt Restructuring (CDR) initiative and the Business Transfer Agreement (BTA) with Hospira

The Company was admitted by Corporate Debt Restructuring (CDR) cell for restructuring its loans and the CDR package was finalized in December 2013 and approved by the CDR EG in March 2014. The Business Transfer Agreement (BTA) entered into with Hospira a part of the CDR initiative was implemented in July 2014 in line with the CDR process.

Shri R Kannan has been appointed as an independent, non-executive director and Ms Soundara Kumar has been appointed as a nominee of the Lenders as per the CDR package. She would be a non-executive director on the Board of Orchid. Shri S Yuvaraj an independent member on the Board vacates the Office of Director.

'Orchid Towers', #313, Valluvar Kottam High Road, Nungambakkam, Chennai 600 034 INDIA

Orchid Pharma FY15 earnings

**For ORCHID CHEMICALS &
PHARMACEUTICALS LTD.**

28/05/15


Executive Vice President - Finance & Secretary

From the Managing Director

"The approval of the CDR package and its implementation during the year with the support of the Lenders and Financial Institutions has helped us put operations of the remaining business back on track. The allocation of part of the sales proceeds for working capital requirements, reduced interest rates on the loans with a moratorium of 2 years for repayment of the principal and interest has improved the level of operations. Given our quality standards and new product pipeline, we are confident of better performance going forward," said Mr K Raghavendra Rao, Managing Director, Orchid Chemicals & Pharmaceuticals Ltd.

About Orchid Pharma

Orchid Chemicals & Pharmaceuticals Ltd. is a leading pharmaceutical company headquartered in Chennai, India involved in the development; manufacture and marketing of diverse bulk actives, formulations and nutraceuticals. With exports spanning more than 75 countries, Orchid is the largest manufacturer-exporter of cephalosporin bulk actives in India and is ranked amongst the Top 5-cephalosporin producers in the world. Orchid's world-class manufacturing infrastructure including USFDA and UK MHRA approved API and dosage form facilities are located at Chennai. Orchid has dedicated state-of-the-art GLP compliant R&D centres for API research, drug discovery and pharmaceutical research at Chennai. Orchid has ISO 14001 and OHSAS 18001 certifications. Orchid is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) in India.

Additional information is available at the company's website at www.orchidpharma.com

Safe Harbour

This release may include forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements that are other than statements of historical fact, including, but not limited to, those that are identified by the use of words such as "anticipates," "believes," "estimates," "expects," "intends," "plans," "predicts," "projects" and similar expressions. Risks and uncertainties that could affect us include, without limitation:

- General economic and business conditions in the markets we operate in;
- The ability to successfully implement our strategies, our research and development efforts, growth and expansion plans and technological changes;
- Changes in the value of the Rupee and other currency changes;
- Changes in the Indian and international interest rates;
- Changes in laws and regulations that apply to our customers, suppliers, and the pharmaceutical industry;
- Increasing competition in and the conditions of our customers, suppliers and the pharmaceutical industry


Should one or more of such risks and uncertainties materialize, or should any underlying assumption prove incorrect, actual outcomes may vary materially from those indicated in the applicable forward-looking statements. Any forward-looking statement or information contained in this presentation speaks only as of the date of the statement. We are not required to update any such statement or information to either reflect events or circumstances that occur after the date the statement or information is made or to account for unanticipated events.

'Orchid Towers', #313, Valluvar Kottam High Road, Nungambakkam, Chennai 600 034 INDIA

Orchid Pharma FY15 earnings

For ORCHID CHEMICALS &
PHARMACEUTICALS LTD.

28/05/15



Executive Vice President - Finance & Secretary